CHUGAI PHARMACEUTICAL CO., LTD.JP:4519
| Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Cash generated from operations | 151,857 | 249,500 | 340,228 | 470,367 | 575,875 | 462,722 |
|---|
| (Increase) decrease in working capital-OpeCF (IFRS) | 4,486 | 6,205 | -64,421 | -83,122 | -183,311 | 130,634 |
|---|
| Payments made for defined benefit plans | -2,652 | -11,540 | -4,656 | -3,665 | -3,739 | -2,887 |
|---|
| Utilization of provisions | -29 | -2 | -26 | -656 | -1,634 | -2,227 |
|---|
| Other | -3,022 | -2,741 | 694 | 776 | 9,004 | -2,244 |
|---|
| Subtotal | 150,639 | 241,423 | 271,820 | 383,700 | 396,194 | 585,998 |
|---|
| Income taxes paid | -31,565 | -34,782 | -66,785 | -104,074 | -152,082 | -176,074 |
|---|
| Net cash provided by (used in) operating activities | 119,074 | 206,641 | 205,035 | 279,626 | 244,112 | 409,925 |
|---|
| Purchase of property, plant and equipment | -71,785 | -53,009 | -57,040 | -65,969 | -62,625 | -71,948 |
|---|
| Purchase of intangible assets | -5,886 | -8,168 | -4,349 | -6,897 | -8,614 | -2,310 |
|---|
| Proceeds from sale of property, plant and equipment | 49 | 119 | -22 | 1,042 | 1,048 | 19,346 |
|---|
| Proceeds from sale of intangible assets | - | - | - | - | 530 | 15,160 |
|---|
| Interest and dividends received | 200 | 197 | 100 | 133 | 281 | 1,482 |
|---|
| Purchase of marketable securities | -263,503 | -256,768 | -248,143 | -362,761 | -518,681 | -545,705 |
|---|
| Proceeds from sale of marketable securities | 264,711 | 230,158 | 211,000 | 325,000 | 442,768 | 546,620 |
|---|
| Purchase of investment securities | -709 | -1,013 | -177 | -9,503 | -321 | -278 |
|---|
| Proceeds from sale of investment securities | 2,863 | 6,743 | 319 | 28 | 151 | 342 |
|---|
| Net cash provided by (used in) investing activities | -74,060 | -81,741 | -98,312 | -118,927 | -145,465 | -37,290 |
|---|
| Interest paid | -5 | -27 | -34 | -48 | -58 | -81 |
|---|
| Lease liabilities paid | - | -8,861 | -8,432 | -9,031 | -7,599 | -7,868 |
|---|
| Dividends paid to owners of parent | -35,010 | -56,370 | -91,442 | -98,644 | -138,220 | -131,594 |
|---|
| Proceeds from exercise of employee share options | 996 | 735 | 440 | 322 | 241 | 217 |
|---|
| Net decrease (increase) in treasury shares | -19 | -25 | -30 | -8 | -5 | -5 |
|---|
| Net cash provided by (used in) financing activities | -35,014 | -66,872 | -99,497 | -107,408 | -145,641 | -139,331 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | -2,215 | -947 | 1,166 | 2,128 | 1,939 | 3,202 |
|---|
| Net increase (decrease) in cash and cash equivalents | 7,785 | 57,081 | 8,393 | 55,419 | -45,584 | 236,505 |
|---|